News | October 15, 2021
Shilpa Medicare raises over Rs. 297 crore through preferential allotment
Equity raise to finance growth and investments in the biological space
Equity raise to finance growth and investments in the biological space
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
The company plans to expand its portfolio in regulated markets aggressively
Next-generation radiofrequency catheter offers first thermal ablation perforator treatment advancement in over 10 years
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
Ectosense’s NightOwl is a leading cloud-connected home sleep apnea test
Its store network grew from 144 stores in March 2019 to 236 stores. It has a presence in 23 cities across Maharashtra, Goa and Karnataka, employing more than 4,600 people.
Cipla is a leading global pharma company
Subscribe To Our Newsletter & Stay Updated
